NCT01371201 2022-08-04
FIRSTMAPPP
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Completed
Clinical Trials
11 trialsNCT00864864 2016-07-07
Sunitinib Tumor Levels in Patients Not on Enzyme-Inducing Anti-Epileptic Drugs Undergoing Debulking Surgery for Recurrent Glioblastoma
Massachusetts General Hospital
Phase EARLY_PHASE1 Completed
NCT00499473 2016-02-29
Sunitinib in Treating Patients With Recurrent Malignant Gliomas
National Cancer Institute (NCI)
Phase 2 Completed
NCT00589784 2016-01-25
Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01462695 2015-08-27
Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00814021 2014-11-05
Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain
Institut Claudius Regaud
Phase 2 Completed
NCT00611728 2014-07-21
Ph I SU011248 + Irinotecan in Treatment of Pts w MG
Duke University
Phase 1 Completed
NCT00387920 2014-01-28
Sunitinib in Treating Young Patients With Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT01100177 2013-03-11
Study of Sunitinib Before and During Radiotherapy in Newly Diagnosed Biopsy-only Glioblastoma Patients
Grupo Español de Investigación en Neurooncología
Phase 2 Completed
NCT00606008 2012-11-19
A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00372775 2011-02-24
Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases
Pfizer
Phase 2 Completed